Tags

Type your tag names separated by a space and hit enter

[Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility].

Abstract

The halothane-caffeine contracture test is presently the most well-established method for identification of malignant hyperthermia susceptibility (MHS) or non-susceptibility (MHN). However, 10-20% of the patients tested are classified as equivocal (MHE), i.e. their susceptibility remains uncertain. A genetic disorder of the calcium releasing ryanodine receptor has been postulated recently. Therefore, 12 patients were tested in addition to the protocol of the European Malignant Hyperthermia Group (EMHG) for dose- and time-dependent contracture after ryanodine application. In this study, contracture of 0.2g appeared significantly earlier in MHS patients (17.5 +/- 1.7 min; n = 5) during cumulative ryanodine exposition (0.4-0.8-1.6-10.0 mumol/l) than in MHN (38.2 +/- 5.4 min; n = 5). A significant difference between MHS (10.0 +/- 1.7 min; n = 6) and MHN (19.8 +/- 0.6 min; n = 3) was also seen after bolus application of ryanodine (10.0 mumol/l). One patient classified as MHE according to the EMHG protocol, manifested as MHN after the ryanodine contracture test. This study supports previous work suggesting the ryanodine contracture test as an improvement in the in-vitro diagnosis of MH susceptibility.

Authors+Show Affiliations

Abteilung für Anästhesiologie, Universitäts-Krankenhaus Eppendorf, Hamburg.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article

Language

ger

PubMed ID

1786306

Citation

Lenzen, C, et al. "[Ryanodine-induced Contractures for the Diagnosis of Malignant Hyperthermia Susceptibility]." Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, vol. 26, no. 8, 1991, pp. 459-63.
Lenzen C, Roewer N, Scholz J, et al. [Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1991;26(8):459-63.
Lenzen, C., Roewer, N., Scholz, J., Rumberger, E., & Schulte am Esch, J. (1991). [Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility]. Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS, 26(8), 459-63.
Lenzen C, et al. [Ryanodine-induced Contractures for the Diagnosis of Malignant Hyperthermia Susceptibility]. Anasthesiol Intensivmed Notfallmed Schmerzther. 1991;26(8):459-63. PubMed PMID: 1786306.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Ryanodine-induced contractures for the diagnosis of malignant hyperthermia susceptibility]. AU - Lenzen,C, AU - Roewer,N, AU - Scholz,J, AU - Rumberger,E, AU - Schulte am Esch,J, PY - 1991/12/1/pubmed PY - 1991/12/1/medline PY - 1991/12/1/entrez SP - 459 EP - 63 JF - Anasthesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie : AINS JO - Anasthesiol Intensivmed Notfallmed Schmerzther VL - 26 IS - 8 N2 - The halothane-caffeine contracture test is presently the most well-established method for identification of malignant hyperthermia susceptibility (MHS) or non-susceptibility (MHN). However, 10-20% of the patients tested are classified as equivocal (MHE), i.e. their susceptibility remains uncertain. A genetic disorder of the calcium releasing ryanodine receptor has been postulated recently. Therefore, 12 patients were tested in addition to the protocol of the European Malignant Hyperthermia Group (EMHG) for dose- and time-dependent contracture after ryanodine application. In this study, contracture of 0.2g appeared significantly earlier in MHS patients (17.5 +/- 1.7 min; n = 5) during cumulative ryanodine exposition (0.4-0.8-1.6-10.0 mumol/l) than in MHN (38.2 +/- 5.4 min; n = 5). A significant difference between MHS (10.0 +/- 1.7 min; n = 6) and MHN (19.8 +/- 0.6 min; n = 3) was also seen after bolus application of ryanodine (10.0 mumol/l). One patient classified as MHE according to the EMHG protocol, manifested as MHN after the ryanodine contracture test. This study supports previous work suggesting the ryanodine contracture test as an improvement in the in-vitro diagnosis of MH susceptibility. SN - 0939-2661 UR - https://www.unboundmedicine.com/medline/citation/1786306/[Ryanodine_induced_contractures_for_the_diagnosis_of_malignant_hyperthermia_susceptibility]_ L2 - http://www.thieme-connect.com/DOI/DOI?10.1055/s-2007-1000616 DB - PRIME DP - Unbound Medicine ER -